REGISTERED
on 06 Jul 2021
Last Applicant/ Owned by
Suite 1700
East Brunswick
NJ
08816
Serial Number
88506119 filed on 09th Jul 2019
Registration Number
6411969 registered on 06th Jul 2021
Correspondent Address
Matthew A. Homyk
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
AVET
Full line of neurological, central nervous system, anti-inflammatory, cardiovascular, renal, anti-microbial, anti-neoplastic, immunomodulatory, hematopoietic, anticoagulant, thrombolytic, antiplatelet, estrogenic, progestin, androgen, thyroid, anti-thyroid, ophthalmic, histamine H2 receptor antagonist, proton pump antagonist, anti-emetic, anti-convulsant, anti-asthmatic and anti-diabetic pharmaceu Read More
Classification Information
Class [005]
Pharmaceutical Products
Full line of neurological, central nervous system, anti-inflammatory, cardiovascular, renal, anti-microbial, anti-neoplastic, immunomodulatory, hematopoietic, anticoagulant, thrombolytic, antiplatelet, estrogenic, progestin, androgen, thyroid, anti-thyroid, ophthalmic, histamine H2 receptor antagonist, proton pump antagonist, anti-emetic, anti-convulsant, anti-asthmatic and anti-diabetic pharmaceutical preparations
First Use Date in General
29th Jan 2020
First Use Date in Commerce
29th Jan 2020
Mark Details
Serial Number
No 88506119
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 134393-01100
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 06th Jul 2021 | REGISTERED-PRINCIPAL REGISTER |
| 02th Jun 2021 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 01st Jun 2021 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 17th May 2021 | STATEMENT OF USE PROCESSING COMPLETE |
| 14th May 2021 | USE AMENDMENT FILED |
| 14th May 2021 | TEAS STATEMENT OF USE RECEIVED |
| 09th Jan 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 07th Jan 2021 | EXTENSION 2 FILED |
| 07th Jan 2021 | TEAS EXTENSION RECEIVED |
| 07th Jan 2021 | EXTENSION 2 GRANTED |